Clinical trial of atorvastatin calcium combined with valsartan in the treatment of essential hypertension
10.13699/j.cnki.1001-6821.2016.12.004
- VernacularTitle:阿托伐他汀钙联合缬沙坦治疗原发性高血压的临床研究
- Author:
Xiao-Juan WEI
1
;
Rong CHANG
;
Xiao-Ling SU
;
Wei LI
Author Information
1. 青海省人民医院心内科
- Keywords:
atorvastatin calcium;
valsartan;
essential hypertension;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2016;32(12):1069-1071
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of atorvastatin calcium combined with valsartan in the treatment of essential hypertension.Methods One hundred and thirty patients with essential hypertension were randomly divided into control group ( n=65 ) and treat-ment group ( n =65 ).Control group was given valsartan 160 mg, qd.Treatment group was received atorvastatin calcium 20 mg, every night on the basis of control group.The clinical efficacy , the expression levels of serum ghrelin and homocysteine , and the incidence of adverse drug reac-tions were compared between two groups.Results After treatment , the total effective rate of treatment group was significantly higher than that of control group ( 86.15% vs 41.54%, P <0.05 ).After treatment , the expression levels of serum serum ghrelin and homocysteine in treatment group were significantly lower than those in control group [(8.18 ±1.17)μg· L-1 vs(10.27 ±1.32)μg· L-1,(10.18 ±2.21)μmol· L-1 vs ( 18.57 ±2.64 )μmol · L-1 , P<0.01 ].There was no significant difference in the incidence of adverse drug reactions between two groups(P>0.05).Conclusion Atorvastatin calcium combined with valsartan have a definitive clinical efficacy for the treatment of essential hypertension , without increasing the incidence of adverse drug reactions.
